FDA Agrees to Review Supplemental NDA for Enzalutamide in Metastatic Prostate …

FDA Agrees to Review Supplemental NDA for Enzalutamide in Metastatic Prostate …

The trial randomized 257 patients with metastatic prostate cancer and 139 patients with non-metastatic prostate cancer whose disease progressed despite treatment with an LHRH analogue therapy or following surgical castration. The primary endpoint of

(Visited 1 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.